#Atrial flutter ablation cpt trial

The maze and modified maze procedures performed on a non-beating heart during cardiopulmonary bypass with concomitant cardiac surgery may be considered medically necessary for treatment of individuals with atrial fibrillation or flutter. Transcatheter radiofrequency ablation or cryoablation not meeting the criteria as indicated this policy is considered experimental/investigational. Development of atrial flutter following the initial procedure or.Repeat transcatheter radiofrequency ablation or cryoablation may be considered medically necessary in individuals with ANY of the following: Symptomatic persistent atrial fibrillation.Symptomatic paroxysmal atrial fibrillation or.As an initial treatment for individuals with recurrent symptomatic paroxysmal atrial fibrillation (greater than one (1) episode, with less than or equal to four (4) episodes in the previous six (6) months) in whom a rhythm-control strategy is desired or.As an alternative to atrioventricular nodal ablation and pacemaker insertion in individuals with class II or III congestive heart failure and symptomatic atrial fibrillation or.Transcatheter radiofrequency ablation or cryoablation to treat atrial fibrillation in individuals who have failed to respond to adequate trials of antiarrhythmic medications may be considered medically necessary for ANY of the following indications: Transcatheter Radiofrequency Ablation or Cryoablation Ischemic or idiopathic cardiomyopathy with ventricular tachycardiaĪ catheter ablation procedure not meeting the criteria as indicated in this policy is considered not medically necessary.Individuals without structural heart disease (i.e., ischemic or idiopathic cardiomyopathy) with symptomatic sustained monomorphic ventricular tachycardia or.Bundle branch reentrant ventricular tachycardia or.For treatment of individuals with ventricular tachycardia with ANY of the following indications:.Symptomatic sustained atrioventricular nodal reentrant tachycardia or.Accessory bypass tract arrhythmia (Wolff-Parkinson-White Syndrome) or.For treatment of individuals with supraventricular tachycardia with ANY of the following indications:.Symptomatic sustained atrioventricular nodal reentrant tachycardia.Ĭomprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters may be considered medically necessary for ANY of the following indications:.Radiofrequency catheter ablation or modification of the atrioventricular junction for ventricular rate control of symptomatic atrial tachyarrhythmias or.Paroxysmal supraventricular tachycardia or.Atrial tachycardia or atrial flutter or.Atrial ablation for elimination of atrial fibrillation or.Intracardiac catheter ablation of atrioventricular node (AV) function may be considered medically necessary for ANY of the following indications:

#Atrial flutter ablation cpt trial

Information about participating trial sites may be found at. should contact their physician to see if their specific situation is appropriate for participation. Persons interested in The ADVENT Trial in the U.S. Clinical studies involving investigational procedures and/or devices may also involve risks that are currently unknown for this type of device or procedure. While these known risks occur infrequently, they can include complications arising from placing catheters in the blood vessels and heart, creation of new heart arrhythmias, interference with the heart’s conduction system requiring a pacemaker, damage to heart structures or surrounding tissue such as nerves or the esophagus, blood clots that may cause stroke or organ damage, or scarring of the pulmonary veins. Based on prior clinical research in Europe, the risk profile associated with the FARAPULSE PFA System and the ablation procedure is consistent with other similar commercially available ablation devices currently in clinical use for cardiac ablation. POTENTIAL RISKS The FARAPULSE Pulsed Field Ablation System is for Investigational Use Only in the United States. These include previous intra-atrial septal patch, known or suspected atrial myxoma, recent heart attack or unstable angina, recent stroke, problems with anticoagulation therapy, current active infection, presence of blood clot in the heart or known problems with obtaining vascular access for heart catheterization. CONTRAINDICATIONS There are a number of reasons why catheter ablation of the pulmonary veins should not be attempted, including using the FARAPULSE Pulsed Field Ablation System. INDICATIONS FOR USE The FARAPULSE Pulsed Field Ablation (PFA) System is indicated for the isolation of pulmonary veins in the treatment of paroxysmal atrial fibrillation. Limited by Federal (or United States) law to investigational use in the United States.